Citius Pharmaceuticals (CTXR) Total Non-Current Liabilities (2014 - 2017)
Citius Pharmaceuticals' (CTXR) quarterly Total Non-Current Liabilities came in at $21.0 million in Q2 2017, up 4.58% YoY from $20.1 million in Q2 2016, and little changed on a QoQ basis from $20.9 million in Q1 2017.
Citius Pharmaceuticals (CTXR) Total Non-Current Liabilities (2014 - 2017) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 4 years of Total Non-Current Liabilities data on file, last reported at $21.0 million in Q2 2017.
- Quarterly Total Non-Current Liabilities rose 4.58% year-over-year to $21.0 million in Q2 2017, while the trailing twelve-month figure through Jun 2017 was $21.0 million (up 4.58% YoY) and the FY2016 annual result came in at $20.3 million, up 784583.24% from the prior year.
- Total Non-Current Liabilities was little changed at $21.0 million in Q2 2017, from $20.9 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $21.0 million in Q2 2017 to a low of -$754531.0 in Q2 2015.
- A 4-year average of $9.1 million and a median of $106518.0 in 2014 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2015 — Total Non-Current Liabilities plunged 97.58% — and 2016, when it jumped 784583.24%.
- Tracing CTXR's Total Non-Current Liabilities over 4 years: stood at -$567816.0 in 2014, then gained by 7.35% to -$526109.0 in 2015, then surged by 4010.17% to $20.6 million in 2016, then rose by 2.01% to $21.0 million in 2017.
- The last three Total Non-Current Liabilities figures came in at $21.0 million (Q2 2017), $20.9 million (Q1 2017), and $20.6 million (Q4 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Citius Pharmaceuticals | 15.60 Mn | 15.60 Mn | 1.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 20.99 Mn |
| Mar 31, 2017 | 20.91 Mn |
| Dec 31, 2016 | 20.57 Mn |
| Sep 30, 2016 | 20.27 Mn |
| Jun 30, 2016 | 20.07 Mn |
| Dec 31, 2015 | -526,109.00 |
| Sep 30, 2015 | 2,583.00 |
| Jun 30, 2015 | -754,531.00 |
| Mar 31, 2015 | -479,475.00 |
| Dec 31, 2014 | -567,816.00 |
| Sep 30, 2014 | 106,518.00 |